Codex Labs Announces 95% SCORAD Reduction in Pediatric Atopic Dermatitis Clinical Trial with L-Histidine Combination Therapy
A New Paradigm in Pediatric Atopic Dermatitis Treatment
A clinical study demonstrating the efficacy of a non-steroidal treatment protocol for pediatric atopic dermatitis (AD) is garnering attention within the industry. Codex Labs Corporation, a U.S.-based skin biotechnology company, will officially announce the results of its non-steroidal pediatric AD clinical trial at the SPD 2026 Annual Conference in July. This trial is considered an innovative approach as it utilizes only biocompatible ingredients without any steroids, offering a safe treatment alternative for pediatric patients. Pediatric patients have thinner skin than adults, making them more susceptible to skin atrophy and systemic absorption side effects from long-term use of topical corticosteroids. Therefore, the emergence of a new treatment that overcomes these concerns is a welcome development in the clinical setting.
95% SCORAD Reduction Suggests Strong Market Potential
The results of this open-label pilot study showed an average 95% reduction in the Atopic Dermatitis Severity Index (SCORAD) in pediatric patients aged 1 to 12 years after an 8-week treatment period. This reduction rate is highly encouraging compared to existing market-leading treatments such as Pfizer's topical PDE4 inhibitor, Eucrisa, and Incyte's topical JAK inhibitor, Opzelura. With the global atopic dermatitis treatment market expected to reach approximately $22.94 billion in 2026 and projected to grow at an annual rate of about 10%, this clinical data, derived without steroids, will be a strong financial asset that facilitates future out-licensing or global partnership discussions with multinational pharmaceutical companies.
Dual Defense Mechanism of L-Histidine and Plant Biotechnology
The Codex Labs protocol combines Bia Skin Barrier Supplement, an oral L-histidine supplement, with a plant biotechnology-based topical agent in an 'Inside-Out' integrated treatment. L-histidine, an essential amino acid, promotes the synthesis of filaggrin, a skin structural protein, in the body, replenishing natural moisturizing factors (NMF) and rebuilding the internal barrier. Simultaneously, Bia Eczema Relief Lotion, which contains plant-derived active ingredients that repair the skin barrier, blocks external harmful substances and improves the skin microbiome, addressing the underlying causes of the disease in a multifaceted manner.
Maximizing Corporate Value by Securing a Pediatric Pipeline
This pediatric clinical trial success builds upon the SCORAD 99% reduction achieved in an adult trial announced earlier in 2026, successfully extending the safety and efficacy to the pediatric population. Early barrier reconstruction is crucial for pediatric atopic dermatitis, which can be a chronic condition lasting a lifetime, and treatments with proven safety are valued even higher in the capital market than those for adults. The promising results of this pilot trial will provide the clinical justification for Codex Labs to move into a large-scale, randomized controlled trial (RCT), and will significantly enhance the attractiveness of the company to global venture capital (VC) firms and pharmaceutical companies that are actively seeking to secure low-toxicity pediatric pipelines.
The global atopic dermatitis market is expected to reach approximately $22.94 billion in 2026, with Sanofi and Regeneron's Dupixent dominating the market with $17.8 billion in sales in 2025. However, there remains a high demand for safe, non-steroidal alternative treatments for infants and young children. The SCORAD 95% reduction demonstrated in this open-label pilot study has garnered significant interest from researchers, as it demonstrates superior efficacy compared to existing market leaders such as Pfizer's Eucrisa and Incyte's Opzelura (2025 sales of $678 million), while avoiding the long-term side effects associated with topical steroids. From an investor's perspective, Codex Labs, a private company, has significantly increased the likelihood of securing early co-development partnerships or technology transfer agreements with major pharmaceutical companies by demonstrating the value of a high-efficacy, non-steroidal pediatric pipeline before entering a large-scale, global Phase 3 trial. In the long term, the commercial success of Bia Skin Barrier Supplement and other products targeting filaggrin synthesis and microbiome improvement could become a key milestone in reshaping the investment landscape of the microbiome and biotechnology skincare segments.